rupatadine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
histamine-H1 receptor antagonists, tricyclic compounds 2413 158876-82-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • rupatadine fumarate
  • rupatadine
  • alergoliber
  • pafinur
  • rinialer
  • rupafin
  • rupax
Rupatadine is a second-generation antihistamine, long-acting histamine antagonist with selective peripheral H1-receptor and platelet activating factor (PAF) antagonistic activities. Some of the metabolites (desloratadine and its hydroxylated metabolites) retain an antihistaminic activity and may partially contribute to the overall efficacy of the drug, maintaining activity for up to 24 hours.
  • Molecular weight: 415.97
  • Formula: C26H26ClN3
  • CLOGP: 5.06
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 0
  • TPSA: 29.02
  • ALOGS: -4.88
  • ROTB: 2

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 50 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 4.029 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.738 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 22.182 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 52.481 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 2.120 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 4.430 % High 1
herg hERG pIC50 5.701 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 30.269 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 141.906 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 1.630 % High 1
kinase-safety-class ACVR2B,AXL,BRAF,CAMK2B,CAMK2D,CDK5,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,NTRK2,PDK4,PRKDC,TGFBR1 15
kinase-selectivity-class AXL,BRAF 2
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.415 High 1
mh-clint Mouse hepatocyte intrinsic clearance 277.971 High 1
mppb Mouse plasma protein binding (% unbound) 1.840 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.265 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 5.100 % High 1
rh-clint Rat hepatocyte intrinsic clearance 214.289 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 17.020 % High 1
rppb Rat plasma protein binding (% unbound) 1.890 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 27.925 uM High 1

Approvals:

DateAgencyCompanyOrphan
Sept. 27, 2017 PMDA Teikoku Seiyaku

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urticaria 543.83 29.16 362 9200 312372 90306513
Pulmonary function test abnormal 456.31 29.16 95 9467 2644 90616241
Chest X-ray abnormal 450.22 29.16 105 9457 4977 90613908
Ear pruritus 439.84 29.16 109 9453 6694 90612191
Blood lactic acid increased 393.22 29.16 105 9457 8673 90610212
Nasal polyps 366.37 29.16 104 9458 10776 90608109
Rhinitis allergic 342.44 29.16 109 9453 16676 90602209
Upper-airway cough syndrome 336.68 29.16 105 9457 15030 90603855
Breath sounds abnormal 334.98 29.16 105 9457 15281 90603604
Sneezing 309.71 29.16 117 9445 29752 90589133
Full blood count abnormal 293.51 29.16 119 9443 36478 90582407
Lacrimation increased 291.45 29.16 109 9453 26953 90591932
Platelet count increased 288.17 29.16 101 9461 20758 90598127
Eye pruritus 284.01 29.16 109 9453 28918 90589967
Asthma 279.04 29.16 219 9343 241941 90376944
Vasculitis 257.52 29.16 95 9467 22598 90596287
Eosinophilia 257.33 29.16 101 9461 28432 90590453
Blood potassium decreased 225.61 29.16 107 9455 47620 90571265
Nasal congestion 221.54 29.16 127 9435 83287 90535598
Wheezing 221.00 29.16 190 9372 237890 90380995
Chest discomfort 208.02 29.16 147 9415 138218 90480667
Rhinorrhoea 206.96 29.16 124 9438 88192 90530693
Angioedema 180.87 29.16 102 9460 64774 90554111
Cough 162.68 29.16 197 9365 368765 90250120
Chronic spontaneous urticaria 106.77 29.16 27 9535 1793 90617092
Skin plaque 99.41 29.16 38 9524 9937 90608948
Dyspnoea 79.84 29.16 238 9324 880717 89738168
Pruritus 77.63 29.16 174 9388 541351 90077534
Mouth breathing 66.10 29.16 12 9550 158 90618727
Muscle tension dysphonia 59.33 29.16 12 9550 287 90618598
Lung disorder 57.74 29.16 75 9487 149808 90469077
Anaphylactic reaction 56.10 29.16 57 9505 87467 90531418
Vascular access site thrombosis 55.77 29.16 9 9553 55 90618830
Vascular access site infection 52.50 29.16 9 9553 83 90618802
Dysphemia 50.67 29.16 17 9545 3053 90615832
Blood immunoglobulin E increased 48.22 29.16 18 9544 4407 90614478
Immunisation reaction 42.66 29.16 11 9551 789 90618096
Perfume sensitivity 40.28 29.16 11 9551 984 90617901
Lipohypertrophy 38.62 29.16 10 9552 729 90618156
Stress 38.19 29.16 45 9517 81350 90537535
Illness 37.94 29.16 45 9517 81924 90536961
Paranasal sinus inflammation 35.12 29.16 9 9553 630 90618255
Vaccination complication 35.06 29.16 10 9552 1049 90617836
Sleep disorder due to a general medical condition 34.00 29.16 32 9530 44706 90574179
Swelling face 33.33 29.16 42 9520 81310 90537575
Sleep disorder 33.25 29.16 68 9494 197962 90420923
Oral pruritus 32.14 29.16 12 9550 2939 90615946
Restrictive pulmonary disease 30.92 29.16 11 9551 2351 90616534
Nasal disorder 30.86 29.16 12 9550 3280 90615605
Oropharyngeal spasm 30.78 29.16 7 9555 295 90618590
Oropharyngeal discomfort 29.50 29.16 15 9547 7720 90611165
Oropharyngeal oedema 29.40 29.16 7 9555 361 90618524
Frustration tolerance decreased 29.20 29.16 15 9547 7881 90611004
Expiratory reserve volume decreased 29.18 29.16 5 9557 46 90618839

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuritis 331.51 43.73 88 5128 6132 42609987
Pulmonary vasculitis 326.12 43.73 87 5129 6179 42609940
Obstructive airways disorder 311.09 43.73 116 5100 24643 42591476
Eosinophilic granulomatosis with polyangiitis 298.47 43.73 87 5129 8551 42607568
Neurological symptom 290.26 43.73 88 5128 9903 42606216
Respiratory symptom 281.09 43.73 88 5128 11018 42605101
Total lung capacity abnormal 280.83 43.73 72 5144 4371 42611748
Forced expiratory volume decreased 259.82 43.73 76 5140 7554 42608565
Pulmonary alveolar haemorrhage 256.17 43.73 88 5128 14728 42601391
Full blood count abnormal 252.19 43.73 105 5111 29771 42586348
Mycotic allergy 245.40 43.73 66 5150 4825 42611294
Mite allergy 243.36 43.73 66 5150 4980 42611139
Dust allergy 239.76 43.73 66 5150 5266 42610853
Conjunctivitis allergic 237.56 43.73 67 5149 5844 42610275
Vasculitis 233.89 43.73 87 5129 18307 42597812
Spirometry abnormal 232.78 43.73 64 5152 5082 42611037
Asthma 227.93 43.73 123 5093 62191 42553928
Pulmonary fibrosis 209.15 43.73 89 5127 26592 42589527
Antineutrophil cytoplasmic antibody positive 205.36 43.73 56 5160 4309 42611810
Hypothyroidism 202.85 43.73 92 5124 31992 42584127
Normochromic normocytic anaemia 201.33 43.73 65 5151 8966 42607153
Wheezing 194.29 43.73 106 5110 54675 42561444
Sleep disorder due to a general medical condition 190.98 43.73 74 5142 17379 42598740
Therapeutic product effect incomplete 181.56 43.73 111 5105 70828 42545291
Nodule 180.45 43.73 65 5151 12469 42603650
Haemoptysis 165.47 43.73 90 5126 46077 42570042
Lung disorder 156.85 43.73 88 5128 47835 42568284
Arteriosclerosis coronary artery 155.27 43.73 65 5151 18612 42597507
Arteriosclerosis 154.23 43.73 64 5152 17925 42598194
Loss of personal independence in daily activities 143.02 43.73 84 5132 49732 42566387
Productive cough 107.56 43.73 71 5145 51496 42564623
Capillaritis 97.42 43.73 27 5189 2201 42613918
Anxiety 93.01 43.73 92 5124 118468 42497651
Hypoxia 75.77 43.73 65 5151 69721 42546398
Thrombosis 72.73 43.73 63 5153 68448 42547671
Pleural thickening 67.70 43.73 15 5201 482 42615637
Condition aggravated 67.62 43.73 117 5099 260637 42355482
Urticaria 60.84 43.73 59 5157 73977 42542142
Bronchial wall thickening 52.71 43.73 15 5201 1345 42614774
Pain in extremity 51.86 43.73 77 5139 150527 42465592
Sleep disorder 48.53 43.73 43 5173 48052 42568067
Pulmonary embolism 48.29 43.73 66 5150 119546 42496573

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urticaria 527.73 24.05 393 14353 318464 110256089
Full blood count abnormal 519.55 24.05 216 14530 55836 110518717
Vasculitis 489.78 24.05 183 14563 35690 110538863
Asthma 471.79 24.05 334 14412 249957 110324596
Ear pruritus 407.26 24.05 109 14637 7151 110567402
Pulmonary function test abnormal 377.10 24.05 95 14651 4905 110569648
Chest X-ray abnormal 372.18 24.05 105 14641 8382 110566171
Upper-airway cough syndrome 367.24 24.05 120 14626 15737 110558816
Wheezing 356.86 24.05 285 14461 254945 110319608
Nasal polyps 326.43 24.05 105 14641 13095 110561458
Pulmonary vasculitis 318.92 24.05 88 14658 6472 110568081
Neuritis 312.94 24.05 89 14657 7310 110567243
Blood lactic acid increased 307.75 24.05 105 14641 15716 110558837
Rhinitis allergic 306.35 24.05 108 14638 17814 110556739
Lacrimation increased 285.61 24.05 119 14627 30831 110543722
Eosinophilic granulomatosis with polyangiitis 284.81 24.05 90 14656 10596 110563957
Total lung capacity abnormal 276.95 24.05 73 14673 4510 110570043
Obstructive airways disorder 273.24 24.05 130 14616 46019 110528534
Sneezing 271.86 24.05 116 14630 31868 110542685
Conjunctivitis allergic 264.67 24.05 77 14669 6854 110567699
Breath sounds abnormal 259.30 24.05 105 14641 25299 110549254
Platelet count increased 252.25 24.05 104 14642 26230 110548323
Respiratory symptom 251.37 24.05 89 14657 14856 110559697
Neurological symptom 247.60 24.05 89 14657 15519 110559034
Eye pruritus 246.35 24.05 109 14637 32666 110541887
Mite allergy 232.82 24.05 67 14679 5736 110568817
Mycotic allergy 231.12 24.05 67 14679 5887 110568666
Dust allergy 230.60 24.05 67 14679 5934 110568619
Spirometry abnormal 227.40 24.05 65 14681 5432 110569121
Pulmonary alveolar haemorrhage 225.47 24.05 89 14657 20061 110554492
Forced expiratory volume decreased 223.63 24.05 79 14667 13097 110561456
Nasal congestion 205.26 24.05 140 14606 98142 110476411
Antineutrophil cytoplasmic antibody positive 200.93 24.05 58 14688 5018 110569535
Rhinorrhoea 199.73 24.05 140 14606 102526 110472027
Blood potassium decreased 191.80 24.05 108 14638 54006 110520547
Normochromic normocytic anaemia 175.80 24.05 66 14680 12991 110561562
Lung disorder 175.80 24.05 164 14582 179883 110394670
Sleep disorder due to a general medical condition 168.58 24.05 98 14648 52014 110522539
Eosinophilia 166.66 24.05 101 14645 57835 110516718
Chest discomfort 159.48 24.05 153 14593 173695 110400858
Angioedema 156.78 24.05 119 14627 98381 110476172
Hypothyroidism 147.79 24.05 102 14644 72797 110501756
Therapeutic product effect incomplete 142.49 24.05 162 14584 223643 110350910
Arteriosclerosis coronary artery 134.22 24.05 66 14680 25052 110549501
Arteriosclerosis 132.11 24.05 65 14681 24702 110549851
Haemoptysis 128.77 24.05 93 14653 71261 110503292
Cough 127.80 24.05 224 14522 461417 110113136
Nodule 123.43 24.05 68 14678 32563 110541990
Loss of personal independence in daily activities 117.14 24.05 121 14625 149899 110424654
Chronic spontaneous urticaria 112.09 24.05 30 14716 1963 110572590
Dyspnoea 104.76 24.05 354 14392 1106518 109468035
Pulmonary fibrosis 93.84 24.05 90 14656 101952 110472601
Capillaritis 92.67 24.05 27 14719 2412 110572141
Skin plaque 88.40 24.05 40 14706 12605 110561948
Pruritus 85.55 24.05 218 14528 581342 109993211
Productive cough 76.49 24.05 85 14661 114220 110460333
Anxiety 56.59 24.05 135 14611 344943 110229610
Acute kidney injury 55.74 24.05 9 14737 635421 109939132
Thrombosis 53.28 24.05 69 14677 108593 110465960
Muscle tension dysphonia 51.12 24.05 11 14735 281 110574272
Vascular access site thrombosis 47.50 24.05 9 14737 118 110574435
Vascular access site infection 45.10 24.05 9 14737 157 110574396
Mouth breathing 45.03 24.05 10 14736 297 110574256
Hypoxia 41.19 24.05 67 14679 129448 110445105
Blood immunoglobulin E increased 40.97 24.05 20 14726 7462 110567091
Immunisation reaction 39.98 24.05 11 14735 798 110573755
Dysphemia 38.82 24.05 16 14730 4021 110570532
Bronchial wall thickening 38.80 24.05 15 14731 3192 110571361
Pleural thickening 37.95 24.05 15 14731 3384 110571169
Anaphylactic reaction 37.53 24.05 60 14686 114240 110460313
Perfume sensitivity 36.73 24.05 11 14735 1080 110573473
Anaemia 35.96 24.05 14 14732 547072 110027481
Thrombocytopenia 35.36 24.05 3 14743 348882 110225671
Neutropenia 33.51 24.05 5 14741 374615 110199938
Lipohypertrophy 33.25 24.05 10 14736 996 110573557
Swelling face 29.67 24.05 48 14698 92273 110482280
Illness 29.57 24.05 45 14701 82126 110492427
Lip swelling 29.36 24.05 35 14711 50632 110523921
Pneumonia 29.12 24.05 45 14701 876669 109697884
Food allergy 27.15 24.05 22 14724 19926 110554627
Frustration tolerance decreased 27.10 24.05 16 14730 8715 110565838
Serum sickness-like reaction 26.77 24.05 8 14738 780 110573773
Drug interaction 26.54 24.05 17 14729 500166 110074387
Vaccination complication 25.94 24.05 8 14738 867 110573686
Product availability issue 25.92 24.05 15 14731 7875 110566678
Nasal disorder 25.25 24.05 12 14734 4222 110570331
Stress 25.07 24.05 48 14698 105300 110469253
Restrictive pulmonary disease 24.98 24.05 11 14735 3248 110571305
Oral pruritus 24.79 24.05 11 14735 3309 110571244
Pulmonary function test decreased 24.56 24.05 15 14731 8685 110565868
Idiopathic urticaria 24.25 24.05 6 14740 287 110574266
Diarrhoea 24.19 24.05 75 14671 1139430 109435123

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R06AX28 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Other antihistamines for systemic use
CHEBI has role CHEBI:35842 antirheumatic drug

Related Drugs by ATC class:

R06AX Other antihistamines for systemic use 26 drugs
acrivastineantazolineastemizoleazatadineazelastinebamipinebilastinecyproheptadinedeptropinedesloratadineebastineepinastine show all 26 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Allergic rhinitis indication 61582004
Urticaria indication 126485001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.22 Basic
pKa2 3.82 Basic
pKa3 3.17 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST IC50 8.41 CHEMBL KEGG DRUG
Platelet-activating factor receptor GPCR IC50 5.43 CHEMBL

External reference:

IDSource
D07407 KEGG_DRUG
182349-12-8 SECONDARY_CAS_RN
C0534301 UMLSCUI
CHEBI:135673 CHEBI
CHEMBL91397 ChEMBL_ID
DB11614 DRUGBANK_ID
C103639 MESH_SUPPLEMENTAL_RECORD_UI
133017 PUBCHEM_CID
10103 IUPHAR_LIGAND_ID
7443 INN_ID
2AE8M83G3E UNII
013131 NDDF
013132 NDDF
1162935008 SNOMEDCT_US
1162955009 SNOMEDCT_US
699252008 SNOMEDCT_US
2AE8M83G3E INXIGHT DRUGS

Pharmaceutical products:

None